Immunic Therapeutics

About:

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

Website: https://www.imux.com

Twitter/X: ImmunicInc

Top Investors: HTGF | High-Tech Gruenderfonds, Bayern Kapital, Invus, Biotechnology Value Fund, RTW Investments

Description:

Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.